Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging clinical data suggest it may improve insulin resistance, androgen levels, and ovulation in women with polycystic ovary syndrome. Here is what the research says.
Tirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA suggest meaningful reductions in AHI. Here is what the research says about off-label use.
Oral micronized progesterone (Prometrium) is used off-label for insomnia due to its GABAergic metabolite allopregnanolone. Learn the evidence, dosing, risks, and how it compares to standard sleep aids.
A clinical evidence summary on using oral micronized progesterone (Prometrium) off-label for perimenopause symptoms including hot flashes, sleep disruption, and irregular bleeding.
In MAESTRO-NASH, MASH resolved in 29.9% on 100 mg and 25.9% on 80 mg vs 9.7% on placebo at week 52. Covers F2-F3 dosing and label monitoring.
A clinical evidence summary of Saxenda (liraglutide 3 mg) used off-label for polycystic ovary syndrome (PCOS), covering trial data, hormonal outcomes, weight effects, and prescribing considerations.
A clinical review of TB-500 (thymosin beta-4 active fragment) for muscle recovery, including preclinical evidence, off-label status, dosing protocols, and safety considerations.
A guide to monitoring testosterone cypionate when used off-label for frailty syndrome, including lab schedules, safety signals, and evidence-based protocols.
Wegovy is not FDA-approved for alcohol use disorder. Rodent studies suggest GLP-1 drugs may reduce drinking, but this page covers no human trial data.
Evidence-based safety review of oral micronized progesterone (Prometrium) in geriatric patients aged 65 and older, covering dosing, risks, monitoring, drug interactions, and deprescribing.
State Medicaid coverage for oral micronized progesterone varies widely. Learn formulary tiers, prior authorization rules, step therapy requirements, and how to appeal a denial.
How low-dose oral minoxidil is dosed for hair loss in adults aged 30 to 49, including starting doses, titration patterns, monitoring, and the boundaries between label guidance and individualized prescribing.
If you took too much oral minoxidil, contact Poison Control now. Learn what details matter, which symptoms need 911, and why no universal home dose cutoff is responsible.
Evidence-based guide to oral minoxidil storage conditions, chemical stability data, compounded formulation shelf life, and practical handling tips for low-dose minoxidil tablets.
Find out whether TRICARE covers oral minoxidil for hair loss, what formulary tier it falls on, prior authorization requirements, step therapy rules, and how to appeal a denial.
A detailed look at how Ozempic (semaglutide) is manufactured, what caused its prolonged shortage, and what the current supply outlook means for patients with type 2 diabetes.
A guide to Ozempic (semaglutide) self-injection technique covering pen preparation, site selection, needle handling, dose titration, and troubleshooting common errors.
Evidence-based guide to the peptides women use for anti-aging, including GHK-Cu, collagen peptides, CJC-1295/ipamorelin, BPC-157, and epithalon. Doses, evidence, and safety reviewed.
A monitoring schedule for Prometrium (micronized progesterone), covering baseline labs, follow-up bloodwork, endometrial surveillance, and long-term exam timelines.
Evidence-based guide to bremelanotide (Vyleesi) dosing adjustments in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and monitoring protocols.
The complete history of rapamycin (sirolimus), from its 1972 discovery in Easter Island soil to FDA approval and current longevity research. Mechanism of action, key trials, and clinical development timeline.
Evidence-based guide to rapamycin (sirolimus) dosing in older adults aged 50 to 64, covering off-label longevity protocols, FDA-approved transplant doses, safety monitoring, and age-specific considerations.
A complete timeline of amlodipine's FDA approval, label updates, generic entry, and post-market safety data from 1987 NDA filing through 2026.
A full regulatory timeline of BPC-157 from 2020 through 2026, covering FDA compounding decisions, safety notices, and why this peptide has no approved label.
A clinical comparison of how the FDA and EMA evaluated Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including approval timelines, label restrictions, safety signals, and post-market requirements.
A detailed regulatory timeline of denosumab (Prolia/Xgeva) from initial FDA approval through post-market safety updates, label expansions, and biosimilar developments.
A detailed review of dulaglutide (Trulicity) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including gastrointestinal events, pancreatitis, thyroid concerns, and cardiovascular outcomes from the REWIND trial.
A clinician-focused review of enclomiphene citrate safety signals in the FDA Adverse Event Reporting System (FAERS), regulatory status, compounding considerations, and post-market surveillance data.
A clinical review of oral estradiol's regulatory history, patent field, generic entry, FDA label evolution, and ongoing legal and safety controversies tied to the WHI trial and post-market surveillance.
A clinical comparison of how the FDA and EMA regulate estradiol transdermal patches, including approval history, labeling differences, post-market surveillance, and what these divergences mean for prescribers and patients.
A clinical review of Repatha's FDA approval history, patent disputes with Sanofi/Regeneron, label updates, post-market safety surveillance, and the regulatory path that shaped PCSK9 inhibitor access.
A clinical review of finasteride's FDA approval history, current compounding legal status, official label warnings, and post-market safety surveillance data.
A clinical review of Addyi's FDA approval history, patent disputes, REMS modifications, and the legal battles that shaped flibanserin access for women with HSDD.
A clinical review of ipamorelin's regulatory trajectory from 2020 through 2026, covering FDA compounding oversight, label-equivalent guidance changes, post-market safety data, and what prescribers need to know.
FDA lists Accutane capsules as discontinued, not for safety or effectiveness reasons. Other isotretinoin products remain available through iPLEDGE.
Complete regulatory breakdown of Jatenzo (oral testosterone undecanoate), including its FDA approval history, prescribing label specifics, compounding legal status under federal law, and what patients and clinicians need to know about access.
MK-677 (ibutamoren) has never received FDA approval. Review the full regulatory timeline, clinical trial record, FDA enforcement actions, and safety data for this investigational growth hormone secretagogue.
A complete guide to Mounjaro (tirzepatide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
How the FDA and EMA classify nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including supplement status, novel food authorization, clinical evidence, and what consumers need to know.
Oral micronized progesterone (Prometrium) approval history, label changes, boxed warning removal and endometrial trial evidence from PEPI.
A comprehensive review of FDA label changes for oral micronized progesterone (Prometrium) from 2020 through 2026, including safety updates, boxed warning revisions, and clinical implications for prescribers.
A clinical breakdown of oral micronized progesterone (Prometrium) FAERS safety signals, FDA post-market surveillance findings, label warnings, and what the adverse-event data mean for patients and prescribers.
A clinical review of Ozempic (semaglutide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
A review of pioglitazone (Actos) label content and FDA safety communications relevant to prescribing decisions from 2020 through 2026, covering bladder cancer language, heart failure warnings, bone fracture risk, and off-label NASH/MASH use, with explicit flags where source figures require independent verification.
Current regulatory and compounding status of PT-141 (bremelanotide), including FDA approval history, Vyleesi labeling, 503A/503B compounding rules, and post-market safety data.
A clinical review of bremelanotide (Vyleesi/PT-141) legal history, patent disputes, FDA regulatory pathway, label requirements, and ongoing post-market safety obligations.
Evenity (romosozumab-aqqg) FDA approval under BLA 761062, the label indication for postmenopausal women, monthly dosing and the boxed warning.
The FDA record lists nine Crestor labeling supplement numbers on seven action dates from May 2020 to September 2026.
Rybelsus was FDA approved September 20, 2019, the first oral GLP-1 tablet. See PIONEER trial data, dosing, and safety label updates since approval.
This review covers Saxenda's FDA approval, the removed suicidal behavior warning, generic liraglutide and FDA's compounding proposal.
A detailed comparison of how the FDA and EMA have handled sermorelin acetate, from its original 1997 approval through withdrawal and current compounding status.
A complete regulatory history of sermorelin acetate, from its 1997 FDA approval through voluntary market withdrawal and current 503A compounding status, with clinical trial data and safety context.
A comprehensive review of sermorelin acetate label changes, FDA regulatory actions, compounding pharmacy status, and post-market safety data from 2020 through 2026.
TB-500 (thymosin beta-4 active fragment) has no FDA approval. Learn its current compounding legal status under 503A pharmacy rules, safety data, labeling gaps, and what the regulatory field means for patients.
Where TB-500 (thymosin beta-4 fragment) stands in the FDA pipeline, what clinical trials exist, and what next-generation derivatives may replace it. prepared by the HealthRX.com Editorial Team.
A complete regulatory timeline of topical minoxidil from its original cardiovascular use through OTC reclassification, label expansions, and ongoing post-market safety surveillance.
The FDA topical minoxidil Drug Facts label covers dosing, stop-use for chest pain or rapid heartbeat, and unwanted facial hair growth.
How the FDA and EMA differ on vaginal estradiol approval, labeling, safety monitoring, and prescribing guidance for genitourinary syndrome of menopause.
The Wegovy FDA label covers three indications: adult weight management (BMI ≥30 or ≥27 with a comorbidity), ages 12+, and cardiovascular risk reduction.
A detailed comparison of how the FDA and EMA regulate Zepbound (tirzepatide) for weight management, including approval timelines, label differences, post-market surveillance, and safety monitoring frameworks.